» Articles » PMID: 31008843

Chemotherapy-induced Peripheral Neuropathy: Where Are We Now?

Overview
Journal Pain
Specialties Neurology
Psychiatry
Date 2019 Apr 23
PMID 31008843
Citations 124
Authors
Affiliations
Soon will be listed here.
Abstract

Chemotherapy-induced peripheral neuropathy (CIPN) is a major challenge, with increasing impact as oncological treatments, using potentially neurotoxic chemotherapy, improve cancer cure and survival. Acute CIPN occurs during chemotherapy, sometimes requiring dose reduction or cessation, impacting on survival. Around 30% of patients will still have CIPN a year, or more, after finishing chemotherapy. Accurate assessment is essential to improve knowledge around prevalence and incidence of CIPN. Consensus is needed to standardize assessment and diagnosis, with use of well-validated tools, such as the EORTC-CIPN 20. Detailed phenotyping of the clinical syndrome moves toward a precision medicine approach, to individualize treatment. Understanding significant risk factors and pre-existing vulnerability may be used to improve strategies for CIPN prevention, or to use targeted treatment for established CIPN. No preventive therapies have shown significant clinical efficacy, although there are promising novel agents such as histone deacetylase 6 (HDAC6) inhibitors, currently in early phase clinical trials for cancer treatment. Drug repurposing, eg, metformin, may offer an alternative therapeutic avenue. Established treatment for painful CIPN is limited. Following recommendations for general neuropathic pain is logical, but evidence for agents such as gabapentinoids and amitriptyline is weak. The only agent currently recommended by the American Society of Clinical Oncology is duloxetine. Mechanisms are complex with changes in ion channels (sodium, potassium, and calcium), transient receptor potential channels, mitochondrial dysfunction, and immune cell interactions. Improved understanding is essential to advance CIPN management. On a positive note, there are many potential sites for modulation, with novel analgesic approaches.

Citing Articles

Review of the Interactions Between Anesthetic Agents and Chemotherapeutic Agents in Cancer Cell Lines Studied In Vitro.

Radkowski P, Oniszczuk H, Opolska J, Pawluczuk M, Gowkielewicz M, Grabarczyk L Med Sci Monit. 2025; 31:e947071.

PMID: 40012181 PMC: 11877971. DOI: 10.12659/MSM.947071.


A novel model of paclitaxel-induced peripheral neuropathy produces a clinically relevant phenotype in mice.

Osborn L, Bishop M, Rodriguez K, Redling D, Duplechain E, Stephens K bioRxiv. 2025; .

PMID: 39990336 PMC: 11844414. DOI: 10.1101/2025.02.10.637458.


Chemotherapy-induced peripheral neuropathy and its determinants among adult cancer patients on chemotherapy in northwest Ethiopia oncology centers, 2022.

Habtie T, Abate M, Abebe G, Wolie Z, Alamaw A, Mitiku H Front Oncol. 2024; 14:1420518.

PMID: 39720571 PMC: 11666479. DOI: 10.3389/fonc.2024.1420518.


α9-Containing Nicotinic Acetylcholine Receptors Are Required for RgIA-5474 Attenuation of Chemotherapy-Induced Neuropathic Pain.

Azam L, Christensen S, Riaz Z, Kendell A, Cull J, Hone A ACS Pharmacol Transl Sci. 2024; 7(12):3935-3944.

PMID: 39698293 PMC: 11651205. DOI: 10.1021/acsptsci.4c00454.


Unlocking New Therapeutic Options for Vincristine-Induced Neuropathic Pain: The Impact of Preclinical Research.

Puscasu C, Negres S, Zbarcea C, Chirita C Life (Basel). 2024; 14(11).

PMID: 39598298 PMC: 11595627. DOI: 10.3390/life14111500.


References
1.
Haanpaa M, Attal N, Backonja M, Baron R, Bennett M, Bouhassira D . NeuPSIG guidelines on neuropathic pain assessment. Pain. 2010; 152(1):14-27. DOI: 10.1016/j.pain.2010.07.031. View

2.
van Esbroeck A, Janssen A, Cognetta 3rd A, Ogasawara D, Shpak G, van der Kroeg M . Activity-based protein profiling reveals off-target proteins of the FAAH inhibitor BIA 10-2474. Science. 2017; 356(6342):1084-1087. PMC: 5641481. DOI: 10.1126/science.aaf7497. View

3.
Attal N, Bouhassira D, Gautron M, Vaillant J, Mitry E, Lepere C . Thermal hyperalgesia as a marker of oxaliplatin neurotoxicity: a prospective quantified sensory assessment study. Pain. 2009; 144(3):245-252. DOI: 10.1016/j.pain.2009.03.024. View

4.
Van Hecke O, Kamerman P, Attal N, Baron R, Bjornsdottir G, Bennett D . Neuropathic pain phenotyping by international consensus (NeuroPPIC) for genetic studies: a NeuPSIG systematic review, Delphi survey, and expert panel recommendations. Pain. 2015; 156(11):2337-2353. PMC: 4747983. DOI: 10.1097/j.pain.0000000000000335. View

5.
Sucheston-Campbell L, Clay-Gilmour A, Barlow W, Budd G, Stram D, Haiman C . Genome-wide meta-analyses identifies novel taxane-induced peripheral neuropathy-associated loci. Pharmacogenet Genomics. 2017; 28(2):49-55. PMC: 5824720. DOI: 10.1097/FPC.0000000000000318. View